John Latham
128Patents
22h-index
78Co-inventors
93Inventor score
Filing activity: Apr 28, 1994 → Jun 27, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5582981A | Method for identifying an oligonucleotide aptamer specific for a target | Physics | 241 | Expired |
| US5756291A | Aptamers specific for biomolecules and methods of making | Chemistry; Metallurgy | 190 | Expired |
| US5840867A | Aptamer analogs specific for biomolecules | Chemistry; Metallurgy | 129 | Expired |
| US7935340B2 | Antibodies to IL-6 and use thereof | Chemistry; Metallurgy | 82 | Active |
| US7592429B2 | Sclerostin-binding antibody | Chemistry; Metallurgy | 76 | Expired |
| US7578999B2 | Antibodies specific for sclerostin | Physics | 54 | Active |
| US8323649B2 | Antibodies to IL-6 and use thereof | Emerging Cross-Sectional Technologies | 54 | Active |
| US7381409B2 | Antibodies specific for sclerostin and methods of screening and use therefor | Physics | 53 | Expired |
| US7906117B2 | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever | Chemistry; Metallurgy | 53 | Active |
| US8062864B2 | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies | Chemistry; Metallurgy | 50 | Active |
| US8268582B2 | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy | Chemistry; Metallurgy | 49 | Active |
| US8178101B2 | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia | Chemistry; Metallurgy | 48 | Active |
| US8337847B2 | Methods of treating anemia using anti-IL-6 antibodies | Emerging Cross-Sectional Technologies | 48 | Active |
| US7872106B2 | Sclerostin-binding antibodies | Chemistry; Metallurgy | 47 | Active |
| US7226902B2 | Ligands for TGF-beta binding proteins and uses thereof | Physics | 44 | Expired |
| US7868134B2 | Immunogenic peptides derived from sclerostin | Physics | 42 | Active |
| US8911734B2 | Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 | Emerging Cross-Sectional Technologies | 38 | Active |
| US9255154B2 | Anti-PCSK9 antibodies and use thereof | Physics | 32 | Active |
| US7927863B2 | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy | Chemistry; Metallurgy | 29 | Active |
| US8728473B2 | Methods of preventing or treating pain using anti-NGF antibodies | Emerging Cross-Sectional Technologies | 26 | Active |
| US9085615B2 | Antibodies to IL-6 to inhibit or treat inflammation | Emerging Cross-Sectional Technologies | 24 | Active |
| US9452227B2 | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments | Emerging Cross-Sectional Technologies | 22 | Active |
| US9745373B2 | Anti-CGRP compositions and use thereof | Chemistry; Metallurgy | 18 | Active |
| US9855332B2 | Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels | Emerging Cross-Sectional Technologies | 18 | Active |
| US9708393B2 | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers | Emerging Cross-Sectional Technologies | 18 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.